6.02
price down icon2.27%   -0.14
after-market 시간 외 거래: 6.01 -0.010 -0.17%
loading
전일 마감가:
$6.16
열려 있는:
$5.98
하루 거래량:
27,384
Relative Volume:
2.13
시가총액:
$58.71M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.99%
1개월 성능:
+0.33%
6개월 성능:
+20.16%
1년 성능:
+0.00%
1일 변동 폭
Value
$5.775
$6.10
1주일 범위
Value
$5.5001
$6.29
52주 변동 폭
Value
$3.81
$10.28

Serina Therapeutics Inc Stock (SER) Company Profile

Name
명칭
Serina Therapeutics Inc
Name
전화
(256) 327-9630
Name
주소
601 GENOME WAY, HUNTSVILLE
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
SER's Discussions on Twitter

SER을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SER
Serina Therapeutics Inc
6.02 58.71M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Serina Therapeutics Inc 주식(SER)의 최신 뉴스

pulisher
Jun 17, 2025

Juvenescence Lands $76M Funding and M42 Partnership to Transform Drug Development in Abu Dhabi - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 - GlobeNewswire Inc.

Jun 17, 2025
pulisher
Jun 17, 2025

VivaTech 2025: A record-setting edition with 180,000 visitors - The Globe and Mail

Jun 17, 2025
pulisher
Jun 17, 2025

Serina Therapeutics Congratulates Juvenescence on Securing $150 Million Series B Financing and Strategic Alliance with M42 - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

$150M Biotech Deal: Juvenescence Partners With M42 to Launch AI-Powered Drug Hub in Abu Dhabi - Stock Titan

Jun 17, 2025
pulisher
Jun 10, 2025

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" - StreetInsider

Jun 10, 2025
pulisher
Jun 09, 2025

Registration Is Now Open For Tribe Public’s CEO - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Biotech Bear Market Creates Massive Opportunity: 25% of US Firms Trading Below Enterprise Value - Stock Titan

Jun 09, 2025
pulisher
May 30, 2025

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Globe and Mail

May 30, 2025
pulisher
May 28, 2025

Nvidia's Big Moment Is Just Ahead. Here's What to Watch For. - The Globe and Mail

May 28, 2025
pulisher
May 22, 2025

Serina Therapeutics Appoints Dr. Stephen Brannan to Board of Directors to Enhance CNS Therapeutic Development - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors - The Manila Times

May 22, 2025
pulisher
May 22, 2025

Karuna's $14B Exit Architect Joins Serina Board: CNS Drug Development Expert to Guide Neural Pipeline - Stock Titan

May 22, 2025
pulisher
May 14, 2025

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Parkinson's Drug Developer Serina Therapeutics Expands Team with Equity Incentives Worth 15,000 Shares - Stock Titan

May 14, 2025
pulisher
May 10, 2025

JonesTrading Keeps Their Buy Rating on Serina Therapeutics (SER) - The Globe and Mail

May 10, 2025
pulisher
May 08, 2025

Serina Therapeutics Advances SER-252 for Parkinson’s Disease and Strengthens Leadership and Financial Position - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail

May 07, 2025
pulisher
Apr 29, 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Serina Therapeutics CEO to Showcase Revolutionary CNS Drug Technology: Key Presentation Details Revealed - Stock Titan

Apr 29, 2025
pulisher
Apr 28, 2025

Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million - marketscreener.com

Apr 28, 2025
pulisher
Apr 15, 2025

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Revolutionary Drug Delivery Tech Could Make mRNA Vaccines Safer: New Trial Data - Stock Titan

Apr 15, 2025
pulisher
Apr 09, 2025

Serina Therapeutics closes $5 million funding for Parkinson’s trial By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

Serina Therapeutics Secures $5 Million Funding - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Serina Therapeutics closes $5 million funding for Parkinson’s trial - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Serina Therapeutics Secures $5 Million in Funding to - GlobeNewswire

Apr 08, 2025
pulisher
Apr 08, 2025

Revolutionary Parkinson's Treatment Gets $5M Boost: Serina's New Drug Heads to Clinical Trials - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Serina's Game-Changing POZ Platform Takes Center Stage at Major Healthcare Conference - Stock Titan

Apr 07, 2025
pulisher
Apr 02, 2025

Serina Therapeutics Files For Mixed Shelf Of Upto $100 MillionSEC Filing - MarketScreener

Apr 02, 2025
pulisher
Mar 24, 2025

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire

Mar 24, 2025
pulisher
Mar 11, 2025

Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq

Mar 11, 2025
pulisher
Mar 10, 2025

Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks

Mar 10, 2025
pulisher
Feb 12, 2025

Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire

Feb 12, 2025
pulisher
Feb 12, 2025

Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan

Feb 12, 2025
pulisher
Feb 08, 2025

Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN

Feb 08, 2025
pulisher
Feb 05, 2025

Serina secures additional $5 million for Parkinson's trial - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Earnings To Watch: e.l.f. Beauty (ELF) Reports Q4 Results Tomorrow - The Globe and Mail

Feb 05, 2025
pulisher
Feb 04, 2025

Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia

Feb 04, 2025
pulisher
Feb 03, 2025

Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch

Feb 03, 2025
pulisher
Feb 03, 2025

Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch

Feb 03, 2025
pulisher
Feb 03, 2025

Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 03, 2025
pulisher
Feb 03, 2025

Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks

Feb 03, 2025

Serina Therapeutics Inc (SER) 재무 분석

Serina Therapeutics Inc (SER)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Serina Therapeutics Inc 주식 (SER) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Bailey Gregory
Director
Sep 20 '24
Buy
6.03
1,137
6,851
63,377
Bailey Gregory
Director
Sep 19 '24
Buy
6.11
11,679
71,384
62,240
Bailey Gregory
Director
Sep 18 '24
Buy
6.23
2,709
16,873
50,561
MINTZ STEVEN
Director
Sep 12 '24
Buy
6.47
6,000
38,814
17,443
Bailey Gregory
Director
Aug 20 '24
Buy
8.25
1,776
14,652
47,582
Bailey Gregory
Director
Aug 19 '24
Buy
7.93
6,400
50,760
45,806
Bailey Gregory
Director
Aug 16 '24
Buy
7.31
6,400
46,780
39,406
Bailey Gregory
Director
Aug 15 '24
Buy
6.65
6,400
42,577
33,006
MINTZ STEVEN
Director
Aug 15 '24
Buy
6.59
7,593
50,033
11,443
MINTZ STEVEN
Director
Aug 15 '24
Buy
6.59
1,350
8,896
12,257
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):